Connect your AI

Vaxcyte, Inc. PCVX Operating Lease Liability Payments - 2024 (Lessee)

Operating Lease Liability Payments - 2024 (Lessee) at other companies

ModernaMRNA

——

Krystal Biotech, Inc.KRYS

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Returns & leverage

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s operating lease liability payments - 2024 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vaxcyte, Inc.'s operating lease liability payments - 2024 (lessee)?: Vaxcyte, Inc. (PCVX) reported operating lease liability payments - 2024 (lessee) of $17.34M in Q1 2026.
How has Vaxcyte, Inc.'s operating lease liability payments - 2024 (lessee) changed year-over-year?: Vaxcyte, Inc.'s operating lease liability payments - 2024 (lessee) increased by 60.2% year-over-year, from $10.83M to $17.34M.